Navigation Links
Oregon theory may help design tomorrow's sustainable polymer
Date:12/11/2008

Tomorrow's specialty plastics may be produced more precisely and cheaply thanks to the apparently tight merger of a theory by a University of Oregon chemist and years of unexplained data from real world experiments involving polymers in Europe.

The work, which researchers believe may lead to a new class of materials, is described in a paper appearing in the Dec. 18 issue of the Journal of Physical Chemistry B (online Dec. 11). The findings eventually could prove useful in the fields of engineering, nanotechnology, renewable energy and, potentially, medicine, because proteins, DNA, RNA and other large molecules within cells may well move in the same way as those in plastics.

Traditional theory behind the processing of plastic materials since the 1960s has focused on the movement of individual macromolecules as they move by one another. Materials researchers, under this approach, end up with poorly understood products and unexplained data. The new theory of cooperative motion in liquids of polymers successfully explains these observations by considering the coordinated motion of macromolecules with their surrounding neighbors. The end result could remove guesswork and the costly, time-consuming testing of thousands of samples at various stages of production.

"The level of agreement between the data and the theory is remarkable," said Marina G. Guenza, a professor of theoretical physical chemistry at the UO. "We are making the connection between the chemistry of molecules and how they behave. It is really fundamental science. Our findings are exciting for experimentalists because we can see phenomena that they cannot understand. This theory is now explaining what is happening inside their samples. They are no longer dealing with just a set of data; our theory provides a picture of what is happening."

Guenza simplifies her mathematics-heavy theory -- built on Langevin equations that describe the movement of particles in
'/>"/>

Contact: Jim Barlow
jebarlow@uoregon.edu
541-346-3481
University of Oregon
Source:Eurekalert  

Page: 1 2

Related biology technology :

1. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
2. Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
3. Assured Pharmacy Consolidates Portland, Oregon Pharmacy
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. New unifying theory of lasers advanced by physicists
6. Physicists saved from drowning in complexities of wetting theory
7. Fluid theory confirmed by Foton
8. National Ergonomics Expo Sees 86% On-Site Exhibitor Renewal Rate for 2009; New Products from Contour Design, Equipois, Goldtouch and Herman Miller Win 2008 NECE Attendees Choice New Product Awards
9. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
10. ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection
11. Sigma-Aldrich Introduces MISSION(R) In VIVO QUALITY and iScale Oligos(TM) siRNA, a Superior Quality siRNA Designed for RNAi Research in Animal Models
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Oregon theory may help design tomorrow's sustainable polymer
Oregon theory may help design tomorrow's sustainable polymer
Breaking Biology Technology:Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 2New silicon-germanium nanowires could lead to smaller, more powerful electronic devices 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3